Peri-implantitis Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Non-Surgical, Surgical), By End-User (Dental Clinics, Hospitals), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 11024.43 Million
CAGR (2026-2031)	8.19%
Fastest Growing Segment	Dental Clinics
Largest Market	North America
Market Size (2031)	USD 17679.86 Million

Market Overview

The Global Peri-implantitis Market will grow from USD 11024.43 Million in 2025 to USD 17679.86 Million by 2031 at a 8.19% CAGR. Peri-implantitis is a pathological inflammatory condition characterized by soft tissue inflammation and the progressive loss of supporting bone surrounding a dental implant. The primary driver supporting the market’s growth is the escalating volume of dental implant procedures globally, fueled by an aging population and rising rates of edentulism. As the cumulative number of placed implants increases, the incidence of biological complications such as peri-implantitis naturally rises, creating a sustained demand for diagnostic and therapeutic solutions. According to the American Academy of Implant Dentistry, in 2025, approximately three million individuals in the United States possessed dental implants, illustrating the substantial patient pool susceptible to implant-related disease.

One significant challenge that could impede market expansion is the unpredictability of clinical outcomes associated with current regenerative treatments. The lack of a universally standardized protocol often leads clinicians to opt for implant removal rather than attempting costly and uncertain preservation therapies. This hesitation, compounded by inconsistent insurance reimbursement for peri-implantitis management, deters patient acceptance of restorative treatments and limits the adoption of advanced therapeutic products.

Key Market Drivers

Increasing Volume of Dental Implant Procedures acts as the primary catalyst expanding the Global Peri-implantitis Market, as the rising number of placed implants directly correlates with a higher incidence of biological complications. This surge creates a larger reservoir of patients requiring therapeutic intervention for inflammatory conditions affecting the soft and hard tissues surrounding osseointegrated fixtures. The proliferation of implant therapy is evident in the financial performance of major industry players, indicating a robust trajectory of procedure adoption which naturally feeds into the demand for remedial treatments. According to Dentsply Sirona, February 2024, in the 'Fourth Quarter and Full Year 2023 Results', the Orthodontic and Implant Solutions segment reported a net sales increase of 10.3% in the fourth quarter, underscoring the continued expansion of implant dentistry that underpins the growing prevalence of peri-implant diseases.

Technological Advancements in Regenerative and Laser Therapies are simultaneously propelling market growth by providing clinicians with more predictable and efficient protocols for biofilm decontamination and tissue preservation. Innovations such as electrolytic cleaning systems and advanced laser modalities are overcoming the limitations of mechanical debridement, thereby encouraging higher treatment acceptance rates among patients and practitioners. According to the Straumann Group, January 2024, in the 'Successful treatment of peri-implantitis with GalvoSurge' case report, the electrolytic cleaning system demonstrated the ability to remove bacterial biofilm from the implant surface in just two minutes, significantly streamlining the surgical workflow. The industry's commitment to standardizing these advanced interventions is further highlighted by collaborative efforts to update clinical frameworks; according to the American Academy of Periodontology, June 2025, in the 'AO/AAP consensus on prevention and management of peri-implant diseases and conditions' summary report, 46 expert representatives convened to establish unified evidence-based guidelines for managing these complex conditions.

Download Free Sample Report

Key Market Challenges

The unpredictability of clinical outcomes associated with current regenerative treatments constitutes a substantial barrier to the expansion of the Global Peri-implantitis Market. Despite the availability of various therapeutic products, the absence of a universally standardized protocol creates significant uncertainty for dental professionals regarding the long-term success of preservation therapies. When clinicians cannot assure patients of stable results, they are reluctant to invest in or recommend expensive regenerative procedures. This lack of confidence in the efficacy of existing interventions directly suppresses the volume of restorative treatments performed, thereby stalling the adoption of advanced market solutions.

This clinical uncertainty frequently biases decision-making toward implant removal rather than preservation. Faced with the risk of therapeutic failure and inconsistent insurance reimbursement for management, practitioners often view explantation as a more predictable and financially prudent alternative. This operational preference limits the revenue potential for diagnostic and regenerative products. According to the Academy of Osseointegration, in 2025, clinical data indicated that peri-implantitis affected approximately 22% of patients with dental implants. While this statistic highlights a massive addressable market, the industry fails to fully capitalize on this demand because the perceived unreliability of treatment protocols deters the widespread utilization of preservation therapies.

Key Market Trends

The Integration of Artificial Intelligence and Digital Imaging for Early Detection is fundamentally reshaping the Global Peri-implantitis Market by shifting clinical focus from reactive treatment to predictive monitoring. Cloud-native platforms and AI-driven diagnostics now allow practitioners to identify initial bone loss and soft tissue anomalies with unprecedented precision, standardizing care across diverse practice settings. This technological convergence facilitates real-time data analysis, enabling timely interventions that prevent disease progression before substantial biological complications occur. According to Dentsply Sirona, February 2025, in the 'Fourth Quarter 2024 Earnings' report, the company's DS Core digital platform surpassed 37,000 unique users, reflecting the rapid industry-wide uptake of connected diagnostic ecosystems that underpin this proactive care model.

Strategic Consolidation Through Mergers and Acquisitions in Dental Care is simultaneously creating robust, vertically integrated networks that streamline the delivery of complex implant therapies. Major industry holding companies are aggregating implant systems, digital workflows, and consumables into unified portfolios, thereby enhancing operational efficiency and broadening market access. This consolidation stabilizes the supply chain and provides clinicians with comprehensive solution suites, fostering consistent procedural outcomes and mitigating the fragmentation that often hampers effective peri-implantitis management. According to Envista Holdings Corporation, February 2025, in the 'Envista Reports Fourth Quarter 2024 Results' press release, the company reported quarterly sales of $653 million, underscoring the financial resilience and market dominance of these large-scale consolidated entities in driving the adoption of standardized implant solutions.

Segmental Insights

In the Global Peri-implantitis Market, the Dental Clinics segment is recognized as the fastest-growing end-user category, primarily driven by the increasing patient preference for convenient and specialized outpatient care. These facilities are becoming the primary point of contact for implant maintenance, offering greater accessibility compared to hospitals. The segment's expansion is further supported by the widespread adoption of advanced diagnostic tools and therapeutic technologies, such as laser debridement systems, within private practices. Additionally, the global surge in dental implant procedures necessitates consistent post-procedural monitoring, positioning dental clinics as the essential hub for early detection and cost-effective management of peri-implant complications.

Regional Insights

North America holds the leading position in the global peri-implantitis market, driven by the high volume of dental implant procedures and the subsequent rise in associated inflammatory conditions. The region benefits from established healthcare infrastructure that supports early diagnosis and effective management of oral diseases. Furthermore, the presence of major industry players and consistent product approvals by the U.S. Food and Drug Administration facilitate the availability of therapeutic solutions. High per capita healthcare spending and rising awareness of periodontal health further consolidate North America's dominance in this sector.

Recent Developments

• In February 2025, Geistlich Pharma strengthened its position in the regenerative market by finalizing a strategic investment in ReOss Ltd, a company specializing in customized, 3D-printed bone regeneration solutions. This collaboration secured Geistlich exclusive global marketing and distribution rights for ReOss's patient-specific technologies, such as the Yxoss CBR®. These digital, customized titanium mesh solutions are utilized in complex bone augmentation procedures, which are often necessary for reconstructive therapy following the treatment of advanced peri-implantitis defects. The partnership aims to integrate digital workflows with regenerative biomaterials, providing clinicians with precise tools to manage hard tissue deficiencies and support long-term implant maintenance.
• In October 2024, Integral Dental entered the dental market with the launch of OraclePI, a novel diagnostic test specifically developed for the early detection of peri-implant disease. The product utilizes next-generation genomic sequencing and machine learning technology to analyze the microbiome at the implant site, providing clinicians with a comprehensive insight into the bacterial presence. The test is designed to diagnose the state of infection and generate personalized care plan recommendations, including targeted antibiotic therapies. This development represents a significant advancement in the peri-implantitis market, moving from reactive treatments to proactive, data-driven management of implant health to prevent failure.
• In June 2024, BioHorizons expanded its portfolio with the launch of the Tapered Pro Conical dental implant, designed to enhance peri-implant health and surgical stability. This new product features the company's proprietary Laser-Lok microchannel technology, which is engineered to establish a physical connective tissue attachment and retain crestal bone. By promoting a biological seal around the implant collar, the design aims to reduce the risk of epithelial downgrowth and subsequent peri-implantitis. The launch addressed the market's need for immediate and predictable solutions that support long-term tissue stability and esthetic outcomes, reinforcing the company's focus on preventing peri-implant complications through advanced surface engineering.
• In April 2024, Zircon Medical Management announced the results of a new long-term study regarding its two-piece Patent™ Dental Implant System. Conducted in collaboration with the Medical University of Graz and the University of Düsseldorf, the independent nine-year study monitored patients to assess the long-term health of the surrounding soft and hard tissues. The findings revealed that none of the two-piece zirconia implants placed in the study showed signs of peri-implantitis after nine years of function. The research highlighted the system's "mucophilic" transmucosal surface, which reportedly facilitates strong soft-tissue adhesion, creating a defense barrier against bacteria and effectively mitigating the risk of chronic inflammation and bone loss associated with peri-implant disease.

Key Market Players

• Straumann Group
• Dentsply Sirona Inc.
• Zimmer Biomet Holdings, Inc.
• Nobel Biocare Services AG
• Institut Straumann AG
• BioHorizons IPH, Inc.
• Keystone Dental, Inc.
• Thommen Medical AG
• Neoss Limited
• MegaGen Implant Co., Ltd.

By Type	By End-User	By Region
Non-Surgical Surgical	Dental Clinics Hospitals	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Peri-implantitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peri-implantitis Market, By Type:

• Non-Surgical
• Surgical

• Peri-implantitis Market, By End-User:

• Dental Clinics
• Hospitals

• Peri-implantitis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE